LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aktien・Erasca Inc

Erasca Inc

Geschlossen

12.02 -9.49

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.8

Max

13.1

Schlüsselkennzahlen
By Trading Economics
Einkommen	-154M -183M
EPS	-0.6
Angestellte	103
EBITDA	-5.3M -37M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+57.57% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	10. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.1B 4.3B
Vorheriger Eröffnungskurs	21.51
Vorheriger Schlusskurs	12.02

Erasca Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2026, 19:20 UTC

Wichtige Markttreiber

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5. Juni 2026, 21:27 UTC

Ergebnisse

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. Juni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. Juni 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. Juni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. Juni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. Juni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. Juni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. Juni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. Juni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. Juni 2026, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. Juni 2026, 17:50 UTC

Ergebnisse

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. Juni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. Juni 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. Juni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5. Juni 2026, 15:25 UTC

Ergebnisse

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5. Juni 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5. Juni 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5. Juni 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5. Juni 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer-Vergleich

Kursveränderung

Erasca Inc Prognose

Kursziel

By TipRanks

57.57% Vorteil

12-Monats-Prognose

Durchschnitt 20.91 USD 57.57%

Hoch 30 USD

Tief 12 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Erasca Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Erasca Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.